Emcure Pharma

{
  "main_header": {
    "sid": 10039308,
    "name": "Emcure Pharma",
    "stock_name": "Emcure Pharma",
    "full_name": "Emcure Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/emcure-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,730.70",
    "chg": 17.1,
    "chgp": "1.0%",
    "dir": 1,
    "prev_price": "1,713.60",
    "mcapval": "32,812.26 Cr",
    "mcap": "Small Cap",
    "scripcode": 544210,
    "symbol": "EMCURE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE168P01015",
    "curr_date": "May 25",
    "curr_time": "",
    "bse_nse_vol": "51.81 k",
    "exc_status": "Active",
    "traded_date": "May 25, 2026",
    "traded_date_str": "2026 05 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/emcure-pharma-10039308-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Emcure Pharmaceuticals Ltd Valuation Shifts Amidst Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-valuation-shifts-amidst-market-volatility-4009937",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_valuationdot_4009937.png",
        "date": "2026-05-25 08:02:02",
        "description": "Emcure Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting a recalibration of price attractiveness despite robust financial performance and market returns. This adjustment, coupled with a downgrade in its Mojo Grade from Buy to Hold, invites a closer examination of the company’s current market standing relative to its historical averages and peer group."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-4000693",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_mojoScore_4000693.png",
        "date": "2026-05-20 10:10:56",
        "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Valuation Shifts Signal Caution Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-valuation-shifts-signal-caution-amid-strong-returns-3997949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_valuationdot_3997949.png",
        "date": "2026-05-19 08:03:05",
        "description": "Emcure Pharmaceuticals Ltd has experienced a notable change in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, prompting a reassessment of its price attractiveness amid sector peers and historical benchmarks. Despite strong operational metrics, the stock’s elevated price-to-earnings and price-to-book ratios suggest a cautious stance for investors evaluating entry or exit points."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Valuation Shifts Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-valuation-shifts-amid-market-volatility-3988564",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_valuationdot_3988564.png",
        "date": "2026-05-13 08:02:02",
        "description": "Emcure Pharmaceuticals Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, despite delivering robust returns well above the Sensex benchmark. This recalibration in price attractiveness, driven by elevated price-to-earnings and price-to-book ratios, signals a critical juncture for investors assessing the stock’s future potential within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-3982715",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_mojoScore_3982715.png",
        "date": "2026-05-09 10:10:36",
        "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its performance and prospects."
      },
      {
        "title": "Emcure Pharmaceuticals Drops 8.04%: 5 Key Factors Behind This Week’s Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-drops-804-5-key-factors-behind-this-weeks-decline-3982653",
        "imagepath": "",
        "date": "2026-05-09 10:01:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> New 52-week and all-time high at Rs.1,805 (intraday)</p>\n                    <p><strong>5 May:</strong> Stock hits another 52-week high at Rs.1,830.35</p>\n                    <p><strong>5 May:</strong> Q4 FY26 results reveal strong topline but margin pressures</p>\n                    <p><strong>6 May:</strong> Flat quarterly performance reported amid rising interest costs</p>\n                    <p><strong>8 May:</strong> Week closes at Rs.1,641.60, down 8.04%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,785.15</div></div>\n          ..."
      },
      {
        "title": "Are Emcure Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-emcure-pharmaceuticals-ltd-latest-results-good-or-bad-3978414",
        "imagepath": "",
        "date": "2026-05-06 19:19:53",
        "description": "Emcure Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported consolidated net sales of ₹2,469.70 crores, reflecting a year-on-year growth of 16.70% and a sequential increase of 4.49% from the previous quarter. This growth indicates Emcure's ability to capture market share and maintain revenue momentum in a competitive pharmaceutical landscape.\n\nOn the profitability front, the consolidated net profit reached ₹243.40 crores, marking a significant year-on-year increase of 28.81%. However, the operating margin, which stood at 19.42%, experienced a contraction of 143 basis points from the previous quarter, highlighting challenges related to rising input costs and competitive pricing pressures. The profit after tax margin improved slightly to 9.87% compared to the previous year, yet the overall margin dynamics suggest a need for careful..."
      },
      {
        "title": "Emcure Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-reports-flat-quarterly-performance-amid-margin-pressures-3976687",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_fintrenddot_3976687.png",
        "date": "2026-05-06 08:00:15",
        "description": "Emcure Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving record net sales and robust profit after tax growth over the last six months, rising interest expenses and margin pressures have tempered investor enthusiasm, reflected in a recent downgrade of its Mojo Grade from Buy to Hold."
      },
      {
        "title": "Emcure Pharmaceuticals Q4 FY26: Strong Topline Growth Masks Margin Pressures and Elevated Valuations",
        "link": "https://www.marketsmojo.com/news/result-analysis/emcure-pharmaceuticals-q4-fy26-strong-topline-growth-masks-margin-pressures-and-elevated-valuations-3976503",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_quaterlyResult_3976503.png",
        "date": "2026-05-05 21:01:53",
        "description": "Emcure Pharmaceuticals Ltd. delivered a mixed performance in Q4 FY26, posting a consolidated net profit of ₹243.40 crores, representing a sequential increase of 5.58% quarter-on-quarter and a robust 28.81% year-on-year growth. However, the stock faced significant selling pressure, plunging 5.25% to ₹1,691.45 in the trading session following the results announcement, as investors grappled with margin compression concerns and premium valuations despite the company's strong revenue momentum."
      }
    ],
    "total": 414,
    "sid": "10039308",
    "stock_news_url": "https://www.marketsmojo.com/news/emcure-pharmaceuticals-10039308"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Emcure Pharmaceuticals Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Emcure Pharmaceuticals Ltd Valuation Shifts Amidst Market Volatility

2026-05-25 08:02:02

Emcure Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting a recalibration of price attractiveness despite robust financial performance and market returns. This adjustment, coupled with a downgrade in its Mojo Grade from Buy to Hold, invites a closer examination of the company’s current market standing relative to its historical averages and peer group.

Read full news article

Emcure Pharmaceuticals Ltd is Rated Hold

2026-05-20 10:10:56

Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Emcure Pharmaceuticals Ltd Valuation Shifts Signal Caution Amid Strong Returns

2026-05-19 08:03:05

Emcure Pharmaceuticals Ltd has experienced a notable change in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, prompting a reassessment of its price attractiveness amid sector peers and historical benchmarks. Despite strong operational metrics, the stock’s elevated price-to-earnings and price-to-book ratios suggest a cautious stance for investors evaluating entry or exit points.

Read full news article

Emcure Pharmaceuticals Ltd Valuation Shifts Amid Market Volatility

2026-05-13 08:02:02

Emcure Pharmaceuticals Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, despite delivering robust returns well above the Sensex benchmark. This recalibration in price attractiveness, driven by elevated price-to-earnings and price-to-book ratios, signals a critical juncture for investors assessing the stock’s future potential within the Pharmaceuticals & Biotechnology sector.

Read full news article

Emcure Pharmaceuticals Ltd is Rated Hold

2026-05-09 10:10:36

Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its performance and prospects.

Read full news article

Emcure Pharmaceuticals Drops 8.04%: 5 Key Factors Behind This Week’s Decline

2026-05-09 10:01:59

Key Events This Week

4 May: New 52-week and all-time high at Rs.1,805 (intraday)

5 May: Stock hits another 52-week high at Rs.1,830.35

5 May: Q4 FY26 results reveal strong topline but margin pressures

6 May: Flat quarterly performance reported amid rising interest costs

8 May: Week closes at Rs.1,641.60, down 8.04%

Week Open

Rs.1,785.15

...

Read full news article

Are Emcure Pharmaceuticals Ltd latest results good or bad?

2026-05-06 19:19:53

Emcure Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported consolidated net sales of ₹2,469.70 crores, reflecting a year-on-year growth of 16.70% and a sequential increase of 4.49% from the previous quarter. This growth indicates Emcure's ability to capture market share and maintain revenue momentum in a competitive pharmaceutical landscape. On the profitability front, the consolidated net profit reached ₹243.40 crores, marking a significant year-on-year increase of 28.81%. However, the operating margin, which stood at 19.42%, experienced a contraction of 143 basis points from the previous quarter, highlighting challenges related to rising input costs and competitive pricing pressures. The profit after tax margin improved slightly to 9.87% compared to the previous year, yet the overall margin dynamics suggest a need for careful...

Read full news article

Emcure Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures

2026-05-06 08:00:15

Emcure Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving record net sales and robust profit after tax growth over the last six months, rising interest expenses and margin pressures have tempered investor enthusiasm, reflected in a recent downgrade of its Mojo Grade from Buy to Hold.

Read full news article

Emcure Pharmaceuticals Q4 FY26: Strong Topline Growth Masks Margin Pressures and Elevated Valuations

2026-05-05 21:01:53

Emcure Pharmaceuticals Ltd. delivered a mixed performance in Q4 FY26, posting a consolidated net profit of ₹243.40 crores, representing a sequential increase of 5.58% quarter-on-quarter and a robust 28.81% year-on-year growth. However, the stock faced significant selling pressure, plunging 5.25% to ₹1,691.45 in the trading session following the results announcement, as investors grappled with margin compression concerns and premium valuations despite the company's strong revenue momentum.

Read full news article

View All News